SCHEMBL7122006

SCHEMBL7122006

Nc1cccc(Nc2noc3c(-c4ccccc4)cccc23)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 8/20 0.54
MAPT P10636 3/20 0.47
KDM4E B2RXH2 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
GFER P55789 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
AHR P35869 1/20 0.45
ABCG2 Q9UNQ0 6/20 0.42
BACE1 P56817 1/20 0.38
BACE2 Q9Y5Z0 1/20 0.38
PDE5A O76074 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
ALDH1A1 P00352 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7125162 0.81 ABCG2 (0.57) EPHX2KDM4EKMT2AGAAABCG2
SCHEMBL7119170 0.80 EPHX2 (0.47) EPHX2MAPTKDM4EMEN1KMT2A
SCHEMBL7128403 0.80 EPHX2 (0.45) EPHX2MAPTKDM4EMEN1KMT2A
SCHEMBL7115895 0.77 EPHX2 (0.71) EPHX2MAPTKDM4EMEN1KMT2A
SCHEMBL7127026 0.76 AHR (0.53) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL27024567 0.72 GAA (0.61) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL18561845 0.69 MAOA (0.52) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL809316 0.67 MAPT (1.00) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL29564320 0.67 MAPT (1.00) MAPTKDM4EMEN1KMT2ALMNA
SCHEMBL15946053 0.67 MAOA (0.53) EPHX2MAPTKDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 EPHX2 354/4885MAPT 3896/4885KDM4E 2224/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.